Disease modification in Parkinson's disease

2004 ◽  
Vol 3 (6) ◽  
pp. 362-368 ◽  
Author(s):  
Anthony HV Schapira
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Modification

Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands

2017 ◽  
Vol 97 ◽  
pp. 179-188 ◽  
Author(s):  
Deniz Kirik ◽  
Erik Cederfjäll ◽  
Glenda Halliday ◽  
Åsa Petersén
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Disease Modification

scholarly journals Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience

2021 ◽  
Vol 15 ◽  
Author(s):  
Simon R. W. Stott ◽  
Richard K. Wyse ◽  
Patrik Brundin
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Drug Repurposing ◽  
Disease Modification

The international Linked Clinical Trials (iLCT) program for Parkinson’s to date represents one of the most comprehensive drug repurposing programs focused on one disease. Since initial planning in 2010, it has rapidly grown – giving rise to seven completed, and 15 ongoing, clinical trials of 16 agents each aimed at delivering disease modification in Parkinson’s disease (PD). In this review, we will provide an overview of the history, structure, process, and progress of the program. We will also present some examples of agents that have been selected and prioritized by the program and subsequently evaluated in clinical trials. Our goal with this review is to provide a template that can be considered across other therapeutic areas.

scholarly journals Recent advances in treating Parkinson’s disease

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 260 ◽  
Author(s):  
Wolfgang H. Oertel
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Behavior Disorder ◽  
Symptomatic Therapy ◽  
Rapid Eye Movement Sleep ◽  
Disease Modification ◽  
Prodromal Stage ◽  
Sleep Behavior ◽  
Primary Endpoints ◽  
Non Motor Symptoms

This article summarizes (1) the recent achievements to further improve symptomatic therapy of motor Parkinson’s disease (PD) symptoms, (2) the still-few attempts to systematically search for symptomatic therapy of non-motor symptoms in PD, and (3) the advances in the development and clinical testing of compounds which promise to offer disease modification in already-manifest PD. However, prevention (that is, slowing or stopping PD in a prodromal stage) is still a dream and one reason for this is that we have no consensus on primary endpoints for clinical trials which reflect the progression in prodromal stages of PD, such as in rapid eye movement sleep behavior disorder (RBD) —a methodological challenge to be met in the future.

Sign in / Sign up

Export Citation Format

Share Document